---
document_datetime: 2023-09-21 21:05:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/docetaxel-winthrop-epar-procedural-steps-taken-authorisation_en.pdf
document_name: docetaxel-winthrop-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3955638
conversion_datetime: 2025-12-20 15:46:16.728258
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant  Aventis  Pharma  S.A.  submitted  on  29  November  2006  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Docetaxel  Winthrop,  through  the centralised procedure according to Regulation (EC) No 726/2004.

The  legal  basis  for  this  application  refers  to  Article  10c  of  Directive  2001/83/EC,  as  amended  relating  to  informed  consent  from  the  marketing  authorisation  holder  for  the  authorised  medicinal product Taxotere (EU/1/95/002/001-002).

Scientific Advice: The applicant did not seek scientific advice at the CHMP. Licensing status: The initial product, Taxotere, has been given a Community Marketing Authorisation on 27 November 1995. The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Eric Abadie Co-Rapporteur: Harald Enzmann 2. Steps taken for the assessment of the product · The application was received by the EMEA on 29 November 2006. · The procedure started on 24 December 2006. · The Rapporteur's first Assessment Report was circulated to all  CHMP  members  on 26 January 2007.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP members on 26 January 2007. · The Rapporteur circulated a Joint Assessment Report to all CHMP members on 12 February 2007. · During  the  meeting  on  19 - 22 February 2007,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Docetaxel Winthrop on 22 February 2007. · The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decision on 20 April 2007 Medicinal product no longer authorised